Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography
https://doi.org/10.20862/0042-4676-2016-97-3-173-180
Abstract
Current review describes the prerequisites for clinical application of nuclear imaging with metaiodobenzylguanidine for cardiac sympathetic activity assessment. As the method developed, various quantitative parameters were proposed to evaluate its results. Some of them are still calculated and interpreted differently in various medical centers. This review systemizes the data regarding the attempts of method standardization, and describes factors that inhibit its validation for clinical trials.
About the Authors
A. A. Ansheles
Russian Cardiology Research-and-Production Complex, Ministry of Health of the RF, ul. Tret’ya Cherepkovskaya, 15a, Moscow, 121552, Russian Federation
Russian Federation
MD, PhD, Senior Researcher
Russian Federation
MD, PhD, Senior Researcher
V. B. Sergienko
Russian Cardiology Research-and-Production Complex, Ministry of Health of the RF, ul. Tret’ya Cherepkovskaya, 15a, Moscow, 121552, Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Head of Nuclear Medicine Department
Russian Federation
MD, PhD, DSc, Professor, Head of Nuclear Medicine Department
References
1. Flotats A., Knuuti J., Gutberlet M., Marcassa C., Bengel F.M., Kaufmann P.A. et al. Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC). Eur. J. Nucl. Med. Mol. Imaging. 2011. 38 (1): 201–12.
2. Аншелес А.А., Щиголева Я.В., Сергиенко И.В., Терещенко С.Н. Особенности перфузии и симпатической иннервации миокарда по данным однофотонной эмиссионной компьютерной томографии у пациентов с гипертрофической кардиомиопатией. Кардиологический вестник. 2016. 1: 24–34. [Ansheles A.A., Shchigoleva Ya.V., Sergienko I.V., Tereshchenko S.N. SPECT myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. Kardiologicheskiy Vestnik. 2016. 1: 24–34 (in Russ.).]
3. Flotats A., Carrio I., Agostini D., Le Guludec D., Marcassa C., Schafers M. et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37 (9): 1802–12.
4. Travin M.I. Cardiac autonomic imaging with SPECT tracers. J. Nucl. Cardiol. 2013; 20 (1): 128–43.
5. Сергиенко В.Б., Аншелес А.А. Радионуклидная диагностика с нейротропными радиопрепаратами. М.: Инфра-М; 2014. [Sergienko V.B., Ansheles A.A. Radionuclide imaging with neurotropic radiopharmaceuticals. Moscow: Infra-M; 2014 (in Russ.).]
6. Wieland D.M., Wu J., Brown L.E., Mangner T.J., Swanson D.P., Beierwaltes W.H. Radiolabeled adrenergi neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J. Nucl. Med. 1980; 21 (4): 349–53.
7. Bombardieri E., Giammarile F., Aktolun C., Baum R.P., Bischof Delaloye A., Maffioli L. et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37 (12): 2436–46.
8. Merlet P., Valette H., Dubois-Rande J.L., Moyse D., Duboc D.,Dove P. et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J. Nucl. Med. 1992; 33 (4): 471–7.
9. Sisson J.C., Shapiro B., Meyers L., Mallette S., Mangner T.J., Wieland D.M. et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J. Nucl. Med. 1987; 28 (10): 1625–36.
10. Schofer J., Spielmann R., Schuchert A., Weber K., Schluter M. Iodine-123 meta- iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 1988; 12 (5): 1252–8.
11. Yahara Y., Nomura Y., Okamoto S., Saitou K., Okamoto R., Makino K. et al. Assessment of most appropriate background subtraction method for quantification of 123Imetaiodobenzylguanidine (MIBG) myocardial uptake by comparing with plasma ANP and BNP. Kaku Igaku. 2000; 37 (3): 217–25.
12. Henderson E.B., Kahn J.K., Corbett J.R., Jansen D.E., Pippin J.J., Kulkarni P. et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78 (5 Pt 1): 1192–9.
13. Rabinovitch M.A., Rose C.P., Schwab A.J., Fitchett D.H., Honos G.N., Stewart J.A. et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J. Nucl. Med. 1993; 34 (4): 589–600.
14. Morozumi T., Ishida Y., Tani A., Sato H., Matsuyama T., Ozaki H. et al. Clinical significance of I-123 MIBG myocardial scintigraphy for evaluating the severity of congestive heart failure. Kaku Igaku. 1991; 28 (3): 271–80.
15. Estorch M., Carrio I., Berna L., Lopez-Pousa J., Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J. Nucl. Cardiol. 1995; 2 (2 Pt 1): 126– 32.
16. Imamura Y., Ando H., Mitsuoka W. egashira S., Masaki H., Ashihara T. et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J. Am. Coll. Cardiol. 1995; 26 (7): 1594–9.
17. Ogita H., Shimonagata T., Fukunami M., Kumagai K., Yamada T., Asano Y. et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001; 86 (6): 656–60.
18. Gerson M.C., McGuire N., Wagoner L.E. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J. Card. Fail. 2003; 9 (5): 384–91.
19. Cohen-Solal A., Esanu Y., Logeart D., Pessione F., Dubois C., Dreyfus G. et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J. Am. Coll. Cardiol. 1999; 33 (3): 759– 66.
20. Nakata T., Miyamoto K., Doi A., Sasao H., Wakabayashi T., Kobayashi H. et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J. Nucl. Cardiol. 1998; 5 (6): 579–90.
21. Wakabayashi T., Nakata T., Hashimoto A., Yuda S., Tsuchihashi K., Travin M.I. et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J. Nucl. Med. 2001; 42 (12): 1757–67.
22. Imamura Y., Fukuyama T., Mochizuki T., Miyagawa M., Watanabe K. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ. J. 2001; 65 (3): 155–160.
23. Verberne H.J., Brewster L.M., Somsen G.A., van Eck-Smit B.L. Prognostic value of myocardial 123Imetaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur. Heart J. 2008; 29 (9): 1147–59.
24. Verberne H.J., Habraken J.B., van Eck-Smit B.L., Agostini D., Jacobson A.F. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (3): 547– 53.
25. Verschure D.O., de Wit T.C., Bongers V., Hagen P.J., Sonneck-Koenne C., D'Aron J. et al. 123I-MIBG heart-to-mediastinum ratio is influenced by high-energy photon penetration of collimator septa from liver and lung activity. Nucl. Med. Commun. 2015; 36 (3): 279–85.
26. Nakajima K., Matsubara K., Ishikawa T., Motomura N., Maeda R., Akhter N. et al. Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multiwindow methods for standardization of the heart-to-mediastinum ratio. J. Nucl. Cardiol. 2007; 14 (6): 843–51.
27. Inoue Y., Abe Y., Itoh Y., Asano Y., Kikuchi K., Sakamoto Y. et al. Acquisition protocols and correction methods for estimation of the heart-to-mediastinum ratio in 123I- metaiodobenzylguanidine cardiac sympathetic imaging. J. Nucl. Med. 2013; 54 (5): 707–13.
28. Kobayashi H., Momose M., Kanaya S., Kondo C., Kusakabe K., Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann. Nucl. Med. 2003; 17 (4): 309–13.
29. Matsuo S., Nakajima K., Okuda K., Kawano M., Ishikawa T., Hosoya T. et al. Standardization of the heartto- mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera-collimator combinations. Eur. J. Nucl. Med. Mol. Imaging. 2009; 36 (4): 560–6.
30. Inoue Y., Abe Y., Asano Y., Kikuchi K., Matsunaga K., Iizuka T. et al. An improved method for estimating the heart-to-mediastinum ratio from cardiac sympathetic nerve imaging with low-energy high-resolution collimators. J. Nucl. Cardiol. 2014; 21 (3): 614–21.
31. Agostini D., Belin A., Amar M.H., Darlas Y., Hamon M., Grollier G. et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: A 123I- MIBG scintigraphic study. J. Nucl. Med. 2000; 41 (5): 845–51.
32. Verberne H.J., Somsen G.A., Povinec P., van Eck-Smit B.L., Jacobson A.F. Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)IMIBG myocardial washout. Eur. J. Nucl. Med. Mol. Imaging. 2009; 36 (8): 1322–8.
33. Ji S.Y., Travin M.I. Radionuclide imaging of cardiac autonomic innervation. J. Nucl. Cardiol. 2010; 17 (4): 655–66.
34. Veltman C.E., Boogers M.J., Meinardi J.E., Al Younis I., Dibbets- Schneider P., Van der Wall E.E. et al. Reproducibility of planar (123)I-meta- iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (10): 1599–608.
35. Jacobson A.F., Senior R., Cerqueira M.D., Wong N.D., Thomas G.S., Lopez V.A. et al. Myocardial iodine- 123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J. Am. Coll. Cardiol. 2010; 55 (20): 2212–21.
36. Chen J., Folks R.D., Verdes L., Manatunga D.N., Jacobson A.F., Garcia E.V. Quantitative I- 123 MIBG SPECT in differentiating abnormal and normal MIBG myocardial uptake. J. Nucl. Cardiol. 2012; 19 (1): 92–9.
37. Yamashina S., Yamazaki J. Neuronal imaging using SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2007; 34 (Suppl. 1): S62–73.
38. Лишманов Ю.Б., Чернов В.И. Национальное руководство по радионуклидной диагностике. Томск: STT; 2010. [Lishmanov Yu.B., Chernov V.I. National guidelines of nuclear medicine. Tomsk: STT; 2010 (in Russ.).]
39. Лишманов Ю.Б., Саушкина Ю.В., Минин С.М., Ефимова И.Ю., Кистенева И.В., Попов С.В. Сцинтиграфическая оценка состояния симпатической иннервации сердца и миокардиальной перфузии у пациентов с фибрилляцией предсердий. Российский кардиологический журнал. 2014; 12: 13–18. [Lishmanov Yu.B., Saushkina Yu.V., Minin S.M., Efimova I.Yu., Kisteneva I.V., Popov S.V. Scintigraphic assessment of cardiac sympathetic innervation and myocardial perfusion in patients with atrial fibrillation. Rossiyskiy Kardiologicheskiy Zhurnal (Journal of Cardiology, Russian journal). 2014; 12: 13–8 (in Russ.).]
40. Henneman M.M., Bengel F.M., van der Wall E.E., Knuuti J., Bax J.J. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J. Nucl. Cardiol. 2008. 15 (3): 442–455.
41. Gimelli A., Liga R., Genovesi D., Giorgetti A., Kusch A., Marzullo P. Association between left ventricular regional sympathetic denervation and mechanical dyssynchrony in phase analysis: a cardiac CZT study. Eur. J. Nucl. Med. Mol. Imaging. 2014; 41 (5): 946–55.
42. Сергиенко В.Б., Самойленко Л.Е. Радионуклидная оценка состояния симпатической иннервации миокарда. Кардиологический вестник. 2006. 2: 43–51. [Sergienko V.B. Samoylenko L.E. Radionuclide assessment of the sympathetic innervation of the myocardium. Kardiologicheskiy Vestnik. 2006; 2: 43–51 (in Russ.).]
43. Сергиенко В.Б., Аншелес А.А., Шульгин Д.Н. Применение радиофармпрепарата 123/131I-МИБГ для радионуклидной диагностики поражений сердца и гормонально
44. активных опухолей (методические рекомендации). Радиационная онкология и ядерная медицина. 2012; 2: 46–62. [Sergienko V.B., Ansheles A.A., Shul’gin D.N. Applications of the 123/131I-MIBG for radionuclide imaging of cardiac lesions and hormonally active tumors (guidelines). Radiatsionnaya Onkologiya i Yadernaya Meditsina Radiation Oncology and Nuclear Medicine, Russian journal). 2012; 2: 46–62 (in Russ.).]
45. Okuda K., Nakajima K., Hosoya T., Ishikawa T., Konishi T., Matsubara K. et al. Semi- automated algorithm for calculating heart-tomediastinum ratio in cardiac Iodine-123 MIBG imaging. J. Nucl. Cardiol. 2011; 18 (1): 82–9.
Review
For citations:
Ansheles A.A., Sergienko V.B. Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Journal of radiology and nuclear medicine. 2016;97(3):173-180. (In Russ.) https://doi.org/10.20862/0042-4676-2016-97-3-173-180
Views:
786
Email this article 